Core Viewpoint - Manulife Financial Corporation (00945.HK) plans to initiate a "normal course issuer bid" subject to approval from the Toronto Stock Exchange, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The "normal course issuer bid" plan has been approved by the Office of the Superintendent of Financial Institutions Canada [1] - As of January 31, 2026, Manulife has approximately 1.6767 billion issued and outstanding common shares [1] - The repurchase of common shares is part of Manulife's capital management strategy aimed at maintaining a robust regulatory capital ratio while also creating value for shareholders [1]

新聞稿 除非另有註明，所有金額均按加元呈列 TSX/NYSE/PSE: MFC SEHK: 945 此外，宏利可根據適用法律，在加拿大及美國以外地區回購其普通股。在獲得監管機構批准的 前提下，宏利亦可根據適用的證券監管機構頒佈的發行人要約豁免令，以私人協議方式直接向 其他持有人購入普通股。根據證券監管機構頒佈的豁免令進行的任何私人購股交易，一般會以 較當時市價有折讓的價格進行。宏利亦可採用衍生工具相關安排支援其回購活動，包括沽售認 沽期權、訂立遠期購股協議、加速股份回購交易、其他股權合約，或以其他方式購入股份。上 述任何安排均須獲得監管機構批准，並按適用證券法在獲許可的條款及時間内進行。通過「常 規發行人要約」及所有其他可能安排回購的普通股總數，將不會超過4,200萬股。 在獲得監管機構批准的前提下，宏利有意不時與註冊投資經紀商訂立既定計劃，以便在宏利因 內部交易禁售期、內幕交易規則或其他因素而通常無法在市場上進行回購時，仍可購入其普通 股。任何此等計劃均須按照適用的加拿大證券法例及美國聯邦證券法例制定。 即時發佈 2026年2月11日 宏利宣佈計劃啓動「常規發行人要約」計劃 加拿大多倫多 – 宏利金融有限公 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | | | --- | --- | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | | | 股票發行人現金股息公告 | | | | | 發行人名稱 | 宏利金融有限公司 | | | | 股份代號 | 00945 | | | | 多櫃檯股份代號及貨幣 | 不適用 | | | | 相關股份代號及名稱 | 不適用 | | | | 公告標題 | 宏利宣布派發普通股股息 | | | | 公告日期 | 2026年2月11日 | | | | 公告狀態 | 新公告 | | | | 股息信息 | | | | | 股息類型 | 第四季度 | | | | 股息性質 | 普通股息 | | | | 財政年末 | 2025年12月31日 | | | | 宣派股息的報告期末 | 2025年12月31日 | | | | 宣派股息 | 每 股 0.485 CAD | | | | 股東批准日期 | 不適用 | | | ...

新聞稿 宏利金融有限公司是全球領先的金融服務供應商，致力於幫助大眾輕鬆作出明智抉擇，實現精彩 人生。本公司為個人、團體及企業提供理財建議及保險方案，全球總部設於加拿大多倫多，在加 拿大、亞洲及歐洲以「宏利」名稱營運，而在美國主要以「恒康」名稱經營業務。通過「宏利財 富與資產管理」，我們為全球個人客戶、機構客戶及退休計劃成員，提供投資、理財建議及退休計 劃服務。截至 2024 年底，本公司有超過 37,000 員工、超過 109,000 代理人，以及數以萬計的經 銷合作夥伴，為逾 3,600 萬客戶提供服務。本公司在多倫多、紐約及菲律賓證券交易所以股份代 號 MFC 上市，並在香港交易所以股份代號 945 上市。 並非所有產品及服務均在所有司法管轄區提供。詳情請瀏覽 manulife.com。 Fiona McLean Derek Theobalds Manulife Manulife 437-441-7491 416-254-1774 除非另有註明，所有金額均按加元呈列 TSX/NYSE/PSE: MFC SEHK: 945 即時發佈 2026 年 2 月 11 日 宏利將普通股股息上調 10.2% 多倫多 ...

TSX/NYSE/PSE: MFC SEHK: 945 除非另有註明，所有金額均按加元呈列 宏利公佈 2025 年全年及第四季業績 多倫多 – 2026 年 2 月 11 日 – 宏利金融有限公司（「宏利」或「本公司」）宣佈截至 2025 年 12 月 31 日的全年及 第四季業績，全年核心盈利及保險新造業務表現 1均創下新高，並宣佈普通股股息上調 10.2%。 2025 年全年及第四季業績的主要重點包括： 「2025 年對宏利而言是具有重要意義的一年。我們的核心盈利創下新高，完成多項具針對性的策略投資，並推 出了優化企業策略。在所有保險業務板塊中，我們均錄得超過 20% 的新造業務 CSM 增長，帶動 CSM 餘額錄 得雙位數升幅，為未來的盈利貢獻奠定了穩固基礎。通過審慎的資本部署，我們進一步強化多元化業務佈局，包 括收購 Comvest Credit Partners，宣佈與 Mahindra 合作成立合資企業進軍印度人壽保險市場 9，在迪拜國際金 融中心設立高淨值客戶辦事處，以及達成收購施羅德印尼的協議 10。這些舉措擴充了我們為客戶提供的世界級投 資及保險方案。此外，Evident AI 將宏利評為 ...

Core Viewpoint - Manulife Financial Corporation has filed its 2025 audited annual financial statements and related Management's Discussion and Analysis (MD&A) with securities regulators, indicating compliance with regulatory requirements and transparency in financial reporting [1] Group 1 - The financial statements pertain to the year ended December 31, 2025, showcasing the company's financial performance for that period [1] - The filings have been made with both the Canadian Securities Administrators and the U.S. Securities and Exchange Commission on Form 40-F, highlighting the company's cross-border regulatory compliance [1] - The information is accessible on the company's website, providing investors with easy access to financial results and reports [1]

TSX/NYSE/PSE: MFC SEHK: 945 C$ unless otherwise stated Manulife Reports Full Year and Fourth Quarter 2025 Results "2025 was a defining year for Manulife, with record core earnings, targeted strategic investments, and the launch of our refreshed strategy. We delivered 20% plus new business CSM growth across all insurance segments, contributing to double-digit growth in our CSM balance and positioning us well for future earnings generation. Through disciplined capital deployment, we further strengthened our d ...

Core Viewpoint - Manulife Financial Corporation has announced a 10.2% increase in its quarterly common shareholders' dividend, raising it to $0.485 per share, effective March 19, 2026 [1]. Group 1: Dividend Announcement - The Board of Directors declared a dividend increase of 4.5 cents per share, resulting in a new dividend of $0.485 per share [1]. - The dividend is payable to shareholders of record as of February 25, 2026 [1]. - The company will purchase common shares on the open market for its Canadian and U.S. Dividend Reinvestment and Share Purchase Plans, with no applicable discounts on the purchase price [1]. Group 2: Company Overview - Manulife is a leading international financial services provider, operating under the name Manulife in Canada, Asia, and Europe, and as John Hancock in the United States [1]. - The company offers financial advice, insurance, and investment services, serving over 36 million customers globally [1]. - As of the end of 2024, Manulife had more than 37,000 employees and over 109,000 agents [1].

Core Insights - Manulife Financial Corporation reported record core earnings and insurance new business results for the year 2025, with a 10.2% increase in common share dividends [1][2] - The company announced a new Normal Course Issuer Bid program to repurchase up to 2.5% of outstanding common shares, expected to commence in late February 2026 [1][2] - The company achieved over 20% growth in new business CSM across all insurance segments, contributing to double-digit growth in CSM balance [1][3] Financial Performance - Core earnings for 2025 reached $7.5 billion, a 3% increase from 2024, with 4Q25 core earnings at $2.0 billion, up 5% year-over-year [3][4] - Net income attributed to shareholders for 2025 was $5.6 billion, a $0.2 billion increase compared to 2024, while 4Q25 net income was $1.5 billion, down $0.1 billion from 4Q24 [3][4] - The company reported a core EBITDA margin improvement of 260 basis points in Global WAM [1][2] Business Segments Performance - In Asia, net income attributed to shareholders increased by 22% to $2.1 billion, with core earnings up 18% [3][4] - Canada saw a net income decrease of 43% to $1.3 billion, while core earnings increased by 6% [3][4] - The U.S. segment reported a net income loss of $367 million, with core earnings down 22% [3][4] Strategic Initiatives - Manulife entered the Indian life insurance market through a joint venture with Mahindra, expanding its global footprint [1][2] - The company acquired 75% of Comvest Credit Partners, enhancing its private credit capabilities [2][3] - A new simplified lending suite was launched in Canada to streamline the lending experience for high-net-worth clients [2][3] Customer Engagement and Innovation - The company launched the Manulife Longevity Institute, investing $350 million through 2030 to promote healthier and financially secure lives [2][3] - Manulife deployed GenAI sales enablement solutions across multiple markets, enhancing client interactions and sales performance [2][3] - A strategic collaboration with Bupa International Limited was established to enhance healthcare access for customers in Hong Kong [2][3] Market Trends and Challenges - Global WAM experienced net outflows of $14.3 billion in 2025, compared to net inflows of $13.3 billion in 2024, driven by lower net sales through third-party intermediaries [4][5] - The company faced challenges in the U.S. segment due to unfavorable life insurance claims experience and lower investment spreads [3][4] - Despite macroeconomic uncertainties, the company remains focused on disciplined execution and sustainable growth [1][2]

Core Viewpoint - Manulife Financial Corporation intends to launch a Normal Course Issuer Bid (NCIB) to purchase up to 42 million common shares, approximately 2.5% of its outstanding shares, as part of its capital management strategy to enhance shareholder value [1]. Group 1: NCIB Details - The NCIB is subject to approval from the Toronto Stock Exchange (TSX) and has already received approval from the Office of the Superintendent of Financial Institutions (Canada) [1]. - As of January 31, 2026, Manulife had 1,676,743,043 common shares issued and outstanding [1]. - The bid period will commence after TSX acceptance and will last for up to one year, with all shares acquired under the NCIB to be cancelled [1]. Group 2: Purchase Mechanisms - Purchases may occur through TSX, New York Stock Exchange, and alternative trading systems at market prices or other permitted prices [1]. - Manulife may also acquire shares outside Canada and the U.S. and enter into derivative-based programs to support its purchase activities, subject to regulatory approval [1]. - The total number of shares purchased under the NCIB and other arrangements will not exceed 42 million [1]. Group 3: Previous NCIB Performance - Manulife's previous NCIB (2025 NCIB) commenced on February 24, 2025, allowing for the purchase of up to 51.5 million common shares, which was completed by January 22, 2026, at an average purchase price of $44.28 per share [1].